Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MOGAT2 | Q3SYC2 | 4/20 | 0.40 |
| ▸ | MLNR | O43193 | 2/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 6/20 | 0.37 |
| ▸ | PLK1 | P53350 | 3/20 | 0.36 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.36 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.35 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.35 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.35 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.35 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL565911 | 0.94 | MOGAT2 (0.45) | MOGAT2MLNRS1PR1PLK1PLK3 | |
| SCHEMBL566313 | 0.89 | S1PR1 (0.47) | MOGAT2S1PR1PLK1PLK3KAT8 | |
| SCHEMBL575036 | 0.86 | S1PR1 (0.49) | MOGAT2S1PR1PLK1PLK3KAT8 | |
| SCHEMBL566293 | 0.83 | S1PR1 (0.43) | S1PR1PLK1PLK3SPHK1 | |
| SCHEMBL566312 | 0.80 | S1PR1 (0.40) | S1PR1PLK1PLK3KAT8PPARA | |
| SCHEMBL564904 | 0.77 | S1PR1 (0.46) | S1PR1PLK1 | |
| SCHEMBL566444 | 0.76 | S1PR1 (0.45) | MOGAT2S1PR1PPARAS1PR3S1PR4 | |
| SCHEMBL177319 | 0.76 | SPHK1 (0.43) | S1PR1PLK1PLK3S1PR3S1PR4 | |
| SCHEMBL565825 | 0.74 | S1PR1 (0.49) | S1PR1PLK1PLK3S1PR3S1PR4 | |
| SCHEMBL566494 | 0.72 | CARM1 (0.53) | S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181182-B2 | S1P receptors modulators | AKAAL PHARMA PTY LTD (AU) | 2015-11-10 | — | — | US | disclosed |
| US-20120034270-A1 | S1P Receptors Modulators | AKAAL PHARMA PTY LTD (AU) | 2012-02-09 | — | — | US | disclosed |
| EP-2344446-A1 | S1P RECEPTORS MODULATORS | Akaal Pharma Pty Ltd (AU) | 2011-07-20 | — | — | EP | disclosed |
| WO-2010042998-A1 | S1P RECEPTORS MODULATORS | AKAAL PHARMA PTY LTD (AU) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120034270-A1 | S1P Receptors Modulators | S1PR1, S1PR5, S1PR3 | MOGAT2 1672/4885MLNR 1335/4885S1PR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.